Tumor necrosis factor receptor signaling pathway (TNFR signaling)

The Tumor Necrosis Factor (TNF) receptor-linked MAPK/NF-κB signaling pathway is a central regulator of the mammalian immune response and cellular homeostasis (Source: UniProt P19438). Signaling is initiated when the cytokine TNF-α binds to its cell-surface receptors, TNFR1 or TNFR2, triggering the recruitment of intracellular adapter proteins such as TRADD, RIPK1, and TRAF2 (Source: PubMed PMID: 12748650). This molecular assembly serves as a scaffold for two major signaling branches: the activation of the IκB kinase (IKK) complex, which releases NF-κB for nuclear translocation, and the activation of Mitogen-Activated Protein Kinase (MAPK) cascades, including p38, JNK, and ERK (Source: StatPearls, TNF Inhibitors). The NF-κB pathway primarily promotes the expression of genes involved in inflammation and cell survival, while the MAPK pathways regulate diverse processes such as cell growth, differentiation, and cytokine production. Dysregulation or chronic overactivation of this pathway is a key driver in the pathogenesis of numerous autoimmune and inflammatory conditions, such as rheumatoid arthritis and inflammatory bowel disease (Source: PubMed PMID: 28545141). Consequently, this pathway is a major therapeutic target, with several approved biologic drugs designed to neutralize TNF-α or its receptors to interrupt the downstream signaling cascade (Source: FDA Label for Humira).

Other names

TNF-alpha signaling pathwayTNFR-MAPK-NF-kappaB axisTumor necrosis factor-mediated signaling cascadeTNFR1/2 signaling pathway

Therapeutic agents typically neutralize the ligand (TNF-alpha) or block its receptors (TNFR1/TNFR2), preventing the recruitment of adapter proteins and the subsequent activation of the MAPK and NF-kappaB pathways (Source: PubMed PMID: 12748650).